700 patients110,866 observations180 daysLIVE

Patient P-02694

Synthetic patientMETA-24 · Day 176 · 65–74 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 META-24 startedBaseline state S14
  2. Day 67 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 67.

Primary contributors, last 14 days
  • Toxicity-8
  • Nutritional resilience-5
  • Treatment adherence+3

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    92%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 88% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Active minutes
    Wearable
    9 min
    worsening · -5.1 vs previous 14 d
    Sleep duration
    Wearable
    6.8 h
    worsening · -0.4 vs previous 14 d
    Energy level
    Daily log
    3.1/10
    worsening · -0.3 vs previous 14 d
    Steps
    Wearable
    556
    worsening · -765 vs previous 14 d
    GI burden
    Companion
    63.3/100
    worsening · +9.1 vs previous 14 d
    Adherence
    Companion
    42.1 %
    stable · +0.5 vs previous 14 d
    Sleep quality
    Wearable
    39.8/100
    worsening · -8.9 vs previous 14 d
    Glucose, CGM daily mean
    CGM
    147 mg/dL
    worsening · +6.6 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards restoration · 33 from the failing basin, 64 from restoration.

    Would help
    • GI-04 GI Support Protocol
      75% improved among 65 similar · onset 8 d · confidence 97%
    • ME-01 Monitoring Escalation
      100% improved among 42 similar · onset 3 d · confidence 75%
    • NP-02 Dietary Support Protocol
      59% improved among 32 similar · onset 10 d · confidence 75%
    • More protein
      GI -7.5 next day on high-intake days · n 26
    Would not help
    • Keep fat low
      GI +6.8 next day on high-intake days · n 19
    • Keep ultra-processed low
      GI +5.4 next day on high-intake days · n 24
    • Keep histamine low
      GI +5.3 next day on high-intake days · n 23
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -7.5supporter · 95%
    • Dietary fat load
      +6.8detractor · 95%
    • Ultra-processed food
      +5.4detractor · 95%
    • Histamine load
      +5.3detractor · 95%
    • Alcohol
      +2.2no signal · 38%
    • Insoluble fibre
      +1.6no signal · 23%
    • Simple carbohydrates
      +0.8no signal · 15%
    • Caffeine
      +0.6no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Mucosal barrier integrity 80
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • MicrobiomeAkkermansia low → thinner mucus layer
      • Daily logGI symptom score 63 and rising
    • Butyrate / short-chain fatty acid production 80
      • MicrobiomeButyrate capacity 27/100
      • MicrobiomeF. prausnitzii depleted
      • Daily logFibre intake low in recent food logs
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 61
    • Drug metabolism and exposure 20
      • BloodToxicity index 46
    • Autonomic recovery 20
      • Wearable556 steps/day
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • CYP2D6 Rapid metabolizer
      Expected exposure
    Microbiome
    Shannon diversity 3.1 · butyrate capacity 27/100
    • Akkermansia muciniphilaLow
    • Faecalibacterium prausnitziiLow
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeHigh
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    51 ms
    Sleep
    6.4 h
    Steps
    814
    Resting HR
    71 bpm
    Daily log: GI score 63, nutritional resilience 36, adherence 42.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Eat slowly and stop at comfortable fullness — smaller volume, more often
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the dose at the same time relative to your evening meal
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0251662%S14SC-12improved51
    P-0231653%S14GI-04improved51
    P-0253548%S14SC-12improved50
    P-0240147%S14GI-04improved49
    P-0262847%S14SC-12improved47
    P-0267047%S14SC-12improved45
    P-0234846%S14GI-04improved49
    P-0232645%S18NP-02improved44
    P-0250445%S14GI-04improved52
    P-0210343%S14GI-04improved46
    P-0232043%S14NP-02improved50
    P-0236343%S14GI-04improved49